logo-loader
viewRegen Biopharma, Inc.

Regen BioPharma, Inc. announced drug discovery agreement with Eli Lilly and Company

Regen will receive compounds from Lilly for drug discovery purposes

deal_57752e848510c.jpg
As part of the deal, Regen will examine 21,000 Lilly-owned compounds

Shares in Regen BioPharma, Inc (OTCQB: RGBP, OTCQB: RGBPP) shot higher as the firm announced it had entered into a definitive agreement with Eli Lilly and Co (NYSE:LLY).

Regen will receive compounds from Lilly for drug discovery purposes, as well as share structural information on compounds.

It also paves the way for the two companies to negotiate future compound purchase agreements, license agreements, and research collaboration agreements.

“They understand the value of partnering in a confidential manner with smaller entities that may have intellectual property that aligns with their product goals,” Harry Lander, president and chief scientific officer of Regen said.

As part of the deal, Regen will examine 21,000 Lilly-owned compounds in its NR2F6 high-throughput screening program.

NR2F6 is a molecular switch known as an "orphan nuclear receptor," which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate.

Quick facts: Regen Biopharma, Inc.

Price: 0.0002 USD

OTCMKTS:RGBP
Market: PINK
Market Cap: $114.3 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Helix Technologies sells security guarding business in a cash deal

Helix Technologies (OTCQB: HLIX) President of Data Services Garvis Toler joined Steve Darling from Proactive Vancouver with news the company has sold off their security guarding business. Toler explains the rationale behind that decision. Toler also told Proactive what they plan on doing with...

7 hours, 13 minutes ago

2 min read